Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
CWLXF · OTC · United States · Medicinal Chemicals & Botanical Products
In shortC21 Investments Inc. is loss-making, generates cash and holds more cash than debt, with revenue growing (+8.3% last year).
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 7.0% | 40/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -9.9% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -12.0% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 7.1% | 47/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.30× | 42/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.00× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 12.17× | 100/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -3.36 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 3.4% | 34/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 5 | 40/100 |
|---|---|---|
| Years of revenue decline (last 5) | 3 of 5 | 0/100 |
| Revenue growth volatility | 9.1% | 77/100 |
| Operating margin volatility | 10.5% | 13/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 4.1% | 40/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2026 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
4 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 33 | 29 | 28 | 30 | 33 |
| Cost of revenue | 14 | 15 | 17 | 18 | 19 |
| Gross profit | 19 | 13 | 11 | 13 | 14 |
| Selling, general & admin | 9.1 | 9.4 | 9.7 | 11 | 11 |
| Operating income | 9.8 | 4 | 1.5 | 1.3 | 2.3 |
| Interest expense | 1.1 | 0.5 | 0 | 0.3 | 0.2 |
| Pre-tax income | 17 | 4.2 | 0.3 | 0.4 | 1.4 |
| Income tax | 4.9 | 2.8 | 3.5 | 4.2 | 4.6 |
| Net income | 10 | 0.3 | (3.3) | (4) | (3.2) |
| Diluted EPS | $0.08 | $0.00 | −$0.03 | −$0.03 | −$0.03 |
| Diluted shares (millions) | 121 | 123 | 123 | 121 | 118 |
4 older years available with the 10-year history. Essential plan, from €8.25/month →
−3.36 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
8/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: . Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice.
Latest annual report: Mar 31, 2026 · Data updated Jun 12, 2026